STOCK TITAN

GYRE (GYRE) COO sells 22,220 shares after stock option exercises

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported option exercises and related share sales. He exercised stock options covering 22,220 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions.

The common stock sales on May 20 and May 21, 2026 were executed at a weighted average price of $6.15 per share, with actual sale prices ranging from about $6.05 to $6.29 according to the footnotes. After these transactions, Ye directly owns 700,000 shares of GYRE common stock.

Positive

  • None.

Negative

  • None.
Insider Ye Weiguo
Role Chief Operating Officer
Sold 22,220 shs ($137K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 12,820 $0.00 --
Exercise Common Stock 12,820 $0.75 $10K
Sale Common Stock 12,820 $6.15 $79K
Exercise Stock Option (Right to Buy) 9,400 $0.00 --
Exercise Common Stock 9,400 $0.75 $7K
Sale Common Stock 9,400 $6.15 $58K
Holdings After Transaction: Stock Option (Right to Buy) — 904,895 shares (Direct, null); Common Stock — 712,820 shares (Direct, null)
Footnotes (1)
  1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These options are vested in full.
Shares sold 22,220 shares Total GYRE common shares sold in open-market transactions
Weighted average sale price $6.15/share Average price for reported GYRE common stock sales
Options exercised 22,220 shares Common shares acquired through stock option exercises
Exercise price $0.75/share Conversion price of stock options into GYRE common stock
Common shares held 700,000 shares Direct GYRE common stock holdings after transactions
Option expiration date October 31, 2030 Expiration of exercised stock options
open-market sale financial
"transaction_action: "open-market sale" for common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" in derivative entries"
weighted average sale price per share financial
"footnote: "The price reported represents the weighted average sale price per share.""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ye Weiguo

(Last)(First)(Middle)
C/O GYRE THERAPEUTICS, INC.
12730 HIGH BLUFF DRIVE, SUITE 250

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/20/2026M9,400A$0.75709,400D
Common Stock05/20/2026S9,400D$6.15(1)700,000D
Common Stock05/21/2026M12,820A$0.75712,820D
Common Stock05/21/2026S12,820D$6.15(2)700,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.7505/20/2026M9,400 (3)10/31/2030Common Stock9,400$0917,715D
Stock Option (Right to Buy)$0.7505/21/2026M12,820 (3)10/31/2030Common Stock12,820$0904,895D
Explanation of Responses:
1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. These options are vested in full.
/s/ Weiguo Ye05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did GYRE COO Ye Weiguo report in this Form 4 filing for GYRE?

Ye Weiguo reported exercising stock options and selling GYRE common shares. He exercised options for 22,220 shares at $0.75 each, then sold 22,220 shares in open-market transactions at a weighted average price of $6.15 per share over two days.

How many GYRE THERAPEUTICS (GYRE) shares did the COO sell and at what price?

He sold a total of 22,220 GYRE common shares in open-market transactions. The weighted average sale price was $6.15 per share, with individual trades executed within price ranges disclosed in the footnotes between approximately $6.05 and $6.29 per share.

What stock options did the GYRE COO exercise according to the Form 4?

He exercised stock options labeled as "Stock Option (Right to Buy)" for 22,220 underlying common shares. These options carried a conversion or exercise price of $0.75 per share and have an expiration date of October 31, 2030, and are described as vested in full.

How many GYRE common shares does the COO hold after the reported transactions?

Following the reported option exercises and related sales, the COO directly holds 700,000 shares of GYRE common stock. This figure reflects his direct ownership after completing both the option exercises and the two days of open-market sale transactions disclosed in the filing.

Were the GYRE share sales made in single trades or multiple transactions?

The GYRE share sales were executed in multiple transactions on each day. Footnotes state the reported price is a weighted average, with individual trades occurring within specific price ranges, and detailed trade-by-trade information is available upon request from the reporting person.